

New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Gepirone ER (Exxua™)	Antidepressant	Major Depressive Disorder	Launch pending. Approved September 2023.
Zuranolone (Zurzuvae™)	Antidepressant	Major Depressive Disorder	Launch pending. Approved August 2023.
Naloxone Nasal Spray (RiVive™)	Opioid Antagonist	Opioid Overdose	Launch pending. Approved July 2023.
Lidocaine Patch (Lydolyte®)	Topical Anesthetic	Nerve Pain	FDA review pending.
Ansofaxine	Antidepressant	Major Depressive Disorder	FDA review pending.
Oxycodone (Aximris XR™)	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Meloxicam/Rizatriptan	NSAID/Serotonin Agonist	Migraine Headache	FDA review pending.

Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Cariprazine (Vraylar®)	Antipsychotic	Schizophrenia & Bipolar Disorder	Generic approved September 2022.
Apixaban (Eliquis®)	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Albuterol Inhaler (Flovent HFA)	Antiasthmatic	Asthma	Patent expiration 2024.

Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Nalmefene Nasal Spray (Opvee®)	Opioid Antagonist	Opioid Overdose	August 2023
Buprenorphine Depot Injection (Brixadi™)	Opioid Agonist	Treatment of Opioid Addiction	August 2023

Available in the Last 12 Months

Newly Available Generics

Tiotropium (Spiriva [®] Handihaler [®])	Bronchodilator	Chronic Obstructive Pulmonary Disease	August 2023
Indomethacin Suppositories (Indocin [®])	NSAID	Pain	August 2023
Budesonide/Formoterol (Symbicort [®])	Antiasthmatic	Asthma	July 2023
Baclofen Oral Suspension (Fleqsuvy [®])	Skeletal Muscle Relaxant	Spasticity	June 2023
Lurasidone (Latuda [®])	Antidepressant	Depression	February 2023
Lubiprostone (Amitiza [®])	Miscellaneous Gastrointestinal Agent	Constipation	January 2023
Diclofenac Potassium (Cambia [®]) Solution	NSAID	Migraine Headache Treatment	January 2023
Topiramate (Trokenidi XR [®]) ER Capsule	Anticonvulsant	Neuropathic Pain	January 2023

Discontinuations & Withdrawals

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Beclomethasone Nasal (Beconase AQ [®])	Nasal Steroid	Allergies	Anticipated date of ceased distribution is approximately November 2023.